175 related articles for article (PubMed ID: 37695713)
1. [The recombinant human parathyroid hormone, teriparatide as an alternative remedy for the medication-related osteonecrosis of the jaw].
Gera I; Szücs N
Orv Hetil; 2023 Sep; 164(36):1406-1415. PubMed ID: 37695713
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw.
Chopra K; Malhan N
Am J Ther; 2020 Jun; 28(4):e469-e477. PubMed ID: 32618592
[TBL] [Abstract][Full Text] [Related]
3. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
Bilezikian JP
Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
[TBL] [Abstract][Full Text] [Related]
4. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review.
Kim JY; Park JH; Jung HD; Jung YS
J Oral Implantol; 2019 Oct; 45(5):403-407. PubMed ID: 31429640
[TBL] [Abstract][Full Text] [Related]
6. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.
Kakehashi H; Ando T; Minamizato T; Nakatani Y; Kawasaki T; Ikeda H; Kuroshima S; Kawakami A; Asahina I
Int J Oral Maxillofac Surg; 2015 Dec; 44(12):1558-64. PubMed ID: 26304604
[TBL] [Abstract][Full Text] [Related]
7. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw.
Anabtawi M; Tweedale H; Mahmood H
Int J Oral Maxillofac Surg; 2021 Apr; 50(4):501-510. PubMed ID: 32800674
[TBL] [Abstract][Full Text] [Related]
8. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.
Ohbayashi Y; Iwasaki A; Nakai F; Mashiba T; Miyake M
Osteoporos Int; 2020 Mar; 31(3):577-585. PubMed ID: 31768589
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR
J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
11. Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series.
Yoshiga D; Yoshioka I; Habu M; Sasaguri M; Tominaga K
Br J Oral Maxillofac Surg; 2022 Jun; 60(5):604-609. PubMed ID: 34996629
[TBL] [Abstract][Full Text] [Related]
12. Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).
Kwon YD; Kim DY
Dent J (Basel); 2016 Nov; 4(4):. PubMed ID: 29563483
[TBL] [Abstract][Full Text] [Related]
13. Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management.
Abdolrahmani A; Epstein JB; Samim F
Support Care Cancer; 2024 Mar; 32(4):212. PubMed ID: 38443685
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Osteonecrosis of the Jaw.
Yamachika E; Matsubara M; Ikeda A; Matsumura T; Moritani N; Iida S
J Craniofac Surg; 2015 Oct; 26(7):e575-7. PubMed ID: 26468825
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.
Jung J; Yoo HY; Kim GT; Lee JW; Lee YA; Kim DY; Kwon YD
J Bone Miner Res; 2017 Dec; 32(12):2445-2452. PubMed ID: 28815779
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases.
Choi SY; Yoon D; Kim KM; Kim SJ; Kim HY; Kim JW; Park JH
J Korean Assoc Oral Maxillofac Surg; 2024 Apr; 50(2):103-109. PubMed ID: 38693133
[TBL] [Abstract][Full Text] [Related]
17. The use of PTH in the treatment of osteoporosis.
Borba VZ; Mañas NC
Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
[TBL] [Abstract][Full Text] [Related]
18. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
19. The use of parathyroid hormone in the treatment of osteoporosis.
Girotra M; Rubin MR; Bilezikian JP
Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762
[TBL] [Abstract][Full Text] [Related]
20. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
Dobnig H
Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
